Gentian Diagnostics ASA

Regulatory Filings • Oct 3, 2017

A new article published in CC&R is demonstrating the clinical value of plasma Calprotectin as an early biomarker of bacterial infections

A new article published in CC&R is demonstrating the clinical value of plasma Calprotectin as an early biomarker of bacterial infections

Recently, the Critical Care and Resuscitation (CC&R) Journal

published an article demonstrating the advantage of Gentians assay

for calprotectin in blood plasma for the prediction and diagnosis

of bacterial infections in critically ill patients. The study was

based on the prototype of Gentian's recently launched GCAL test.

Sepsis is potentially a life-threatening complication because of a

serious infection, and is the leading source of morbidity and

mortality worldwide. Early detection and initiation of antibiotic

treatment in septic shock is of vital importance since it is

associated with lower mortality.

"The article published in CC&R demonstrates that the predictive

and diagnostic accuracy of plasma calprotectin in patients with

bacterial infection could be superior to that of other traditional

biomarkers. Moreover, calprotectin levels were increased in the

blood of infected patients 24 h before the infection was suspected

and antibiotic therapy was initiated. This suggests that the use

of plasma calprotectin may prevent the unnecessary- and unwanted

prescription of antibiotics, and as a result the associated

problem with multi-resistant bacteria" says Aleksandra Mandic

Havelka, Managing Director in Gentian Diagnostics AB. If used

correctly plasma calprotectin could be a very valuable additional

diagnostic tool to guide the appropriate initiation of antibiotic

therapy and help doctors save the lives of critically ill patients.

The abstract of the article can be found here:

https://www.ncbi.nlm.nih.gov/pubmed/28866970

For further information, please contact:

Bård Sundrehagen

CEO, Gentian Diagnostics

E-mail: Bard.sundrehagen@gentian.no

Cell Phone: +47 924 14 117

ABOUT GENTIAN DIAGNOSTICS AS

Gentian Diagnostics AS is a medical diagnostics company listed on

Merkur Market, Oslo Stock Exchange with the ticker "GENT-ME".

Gentian is headquartered in Moss, Norway, with a representative

office in China and distribution subsidiaries in Sweden and USA.

Gentian designs, develops and markets in vitro diagnostic reagents

(IVD) based on its proprietary Nanosense technology. The goal is

to offer efficient and accurate reagents for major clinical

chemistry platforms with a focus within the areas of kidney

disease, cardiac disease, inflammation and veterinary medicine.

The Nanosense technology will enable users to move assays from low

volume immunology platforms to fully automated, high throughput

instruments with shorter turnaround times, better workflow and

improved cost efficiency.